Results first half 2000

PhotoCure ASA is pleased to present the results for the first half of 2000.

HIGHLIGHTS
- PhotoCure submitted 2nd of May its first Marketing Authorisation Application (MAA) for Metvix® for treatment of pre-cancerous skin lesions (actinic keratosis; AK) in Sweden.
- Patient inclusion in clinical phase III is finished for skin cancer (Basal Cell Carcinoma; BCC) in Europe and is ongoing for AK in Australia and USA.
- Patent application related to PhotoCure’s light source Curelight is accepted in Australia.
- PhotoCure was listed on Oslo Stock Exchange main list the 29th of May. An Initial Public Offering (IPO) prior to the listing was more than 6 times oversubscribed. The company received net NOK 335 million after issue fees and expenses through the share issue.
- Net loss amounted to NOK 28.8 million for the six month period ended 30th of June 2000, which is in accordance with the company’s plan.

2nd quarter report is available on the following link:
http://reports.huginonline.com/788021.pdf

The full report for the 2nd quarter is also available at www.photocure.com.

Presentation for the 2nd quarter 2000 is available on the following link:
http://reports.huginonline.com/788030.pdf

Follow the link below to view this press release in its original format (including tables)